Cargando…

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line

We aimed to explore the molecular substrate underlying EGFR‐TKI resistance and investigate the effects of N‐acetylcysteine (NAC) on reversing EGFR‐TKI resistance. In the current research, the effects of NAC in combination with gefitinib on reversing gefitinib resistance were examined using CCK‐8 ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Wang, Xiao‐Hui, Hu, Jing, Shi, Meng, Zhang, Lu, Chen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013061/
https://www.ncbi.nlm.nih.gov/pubmed/31891230
http://dx.doi.org/10.1002/cam4.2610
_version_ 1783496334731378688
author Li, Jun
Wang, Xiao‐Hui
Hu, Jing
Shi, Meng
Zhang, Lu
Chen, Hong
author_facet Li, Jun
Wang, Xiao‐Hui
Hu, Jing
Shi, Meng
Zhang, Lu
Chen, Hong
author_sort Li, Jun
collection PubMed
description We aimed to explore the molecular substrate underlying EGFR‐TKI resistance and investigate the effects of N‐acetylcysteine (NAC) on reversing EGFR‐TKI resistance. In the current research, the effects of NAC in combination with gefitinib on reversing gefitinib resistance were examined using CCK‐8 assay, combination index (CI) method, matrigel invasion assay, wound‐healing assay, flow cytometry, western blot, and quantitative real‐time PCR (qRT‐PCR). CCK8 assay showed that NAC plus gefitinib combination overcame EGFR‐TKI resistance in non‐small cell lung cancer (NSCLC) cells by lowering the value of half maximal inhibitory concentration (IC50). CI calculations demonstrated a synergistic effect between the two drugs (CI < 1). Matrigel invasion assay and wound healing assay demonstrated a decrease in migration and invasion ability of PC‐9/GR cells after NAC and gefitinib treatment. Flow cytometry displayed enhanced apoptosis in the combination group. Western blot and qRT‐PCR revealed that increased E‐cadherin and decreased vimentin in the combination group. When PP2 was administered with gefitinib, the same effects were seen. Our findings suggest that NAC could restore the sensitivity of gefitinib‐resistant NSCLC cells to gefitinib via suppressing Src activation and reversing epithelial‐mesenchymal transition.
format Online
Article
Text
id pubmed-7013061
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70130612020-03-24 Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line Li, Jun Wang, Xiao‐Hui Hu, Jing Shi, Meng Zhang, Lu Chen, Hong Cancer Med Cancer Biology We aimed to explore the molecular substrate underlying EGFR‐TKI resistance and investigate the effects of N‐acetylcysteine (NAC) on reversing EGFR‐TKI resistance. In the current research, the effects of NAC in combination with gefitinib on reversing gefitinib resistance were examined using CCK‐8 assay, combination index (CI) method, matrigel invasion assay, wound‐healing assay, flow cytometry, western blot, and quantitative real‐time PCR (qRT‐PCR). CCK8 assay showed that NAC plus gefitinib combination overcame EGFR‐TKI resistance in non‐small cell lung cancer (NSCLC) cells by lowering the value of half maximal inhibitory concentration (IC50). CI calculations demonstrated a synergistic effect between the two drugs (CI < 1). Matrigel invasion assay and wound healing assay demonstrated a decrease in migration and invasion ability of PC‐9/GR cells after NAC and gefitinib treatment. Flow cytometry displayed enhanced apoptosis in the combination group. Western blot and qRT‐PCR revealed that increased E‐cadherin and decreased vimentin in the combination group. When PP2 was administered with gefitinib, the same effects were seen. Our findings suggest that NAC could restore the sensitivity of gefitinib‐resistant NSCLC cells to gefitinib via suppressing Src activation and reversing epithelial‐mesenchymal transition. John Wiley and Sons Inc. 2019-12-31 /pmc/articles/PMC7013061/ /pubmed/31891230 http://dx.doi.org/10.1002/cam4.2610 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Li, Jun
Wang, Xiao‐Hui
Hu, Jing
Shi, Meng
Zhang, Lu
Chen, Hong
Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
title Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
title_full Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
title_fullStr Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
title_full_unstemmed Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
title_short Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
title_sort combined treatment with n‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in nsclc cell line
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013061/
https://www.ncbi.nlm.nih.gov/pubmed/31891230
http://dx.doi.org/10.1002/cam4.2610
work_keys_str_mv AT lijun combinedtreatmentwithnacetylcysteineandgefitinibovercomesdrugresistancetogefitinibinnsclccellline
AT wangxiaohui combinedtreatmentwithnacetylcysteineandgefitinibovercomesdrugresistancetogefitinibinnsclccellline
AT hujing combinedtreatmentwithnacetylcysteineandgefitinibovercomesdrugresistancetogefitinibinnsclccellline
AT shimeng combinedtreatmentwithnacetylcysteineandgefitinibovercomesdrugresistancetogefitinibinnsclccellline
AT zhanglu combinedtreatmentwithnacetylcysteineandgefitinibovercomesdrugresistancetogefitinibinnsclccellline
AT chenhong combinedtreatmentwithnacetylcysteineandgefitinibovercomesdrugresistancetogefitinibinnsclccellline